Results 41 to 50 of about 29,580 (292)

How and why systemic inflammation worsens quality of life in patients with advanced cancer [PDF]

, 2017
Introduction: The presence of an innate host systemic inflammatory response has been reported to be a negative prognostic factor in a wide group of solid tumour types in both the operable and advanced setting, both local and distant.
Dolan, Ross D., Horgan, Paul G., McMillan, Donald C., McSorley, Stephen T., Roxburgh, Campbell S.D.   +4 more
core   +1 more source

Plasma inflammatory cytokines and survival of pancreatic cancer patients. [PDF]

, 2018
OBJECTIVES: Inflammation and inflammatory conditions have been associated with pancreatic cancer risk and progression in a number of clinical, epidemiological, and animal model studies.
Babic, A., Barbie, D. A., Brais, L. K., Fuchs, C. S., Kulke, M. H., Morales-Oyarvide, V., Neupane, N. P., Ng, K., Poole, E. M., Rifai, N., Rubinson, D. A., Schnure, N., Welch, M. W., Wolpin, B. M., Wong, K., Yuan, C., Zaman, M. M., Zhang, S.   +17 more
core   +2 more sources

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. [PDF]

, 2018
The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells and resistance to therapy. Activation of JAK/STAT signaling is thought to be a central component of these microenvironment-induced phenotypes.
Aftab, Blake T, Ferguson, Ian D, Hann, Byron C, Lam, Christine, Lin, Yu-Hsiu T, Liu, Hui, Liu, Jun O, Mariano, Margarette C, Mitsiades, Constantine S, Murnane, Megan, Smith, Geoffrey A, Taunton, Jack, Wiita, Arun P, Wong, Sandy W   +13 more
core   +2 more sources

A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies [PDF]

, 2020
With recent advancements in the understanding of vitiligo pathogenesis, Janus kinase (JAK) inhibitors have emerged as a promising new treatment modality, but their effects remain incompletely elucidated.
Alikhan, Mujahed, Jogi, Reena, Nguyen, Julie K, Patel, Anisha B, Schlichte, Megan J   +4 more
core  

Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial

Cancer Medicine, 2021
Preclinical observations that killing of chronic lymphocytic leukemia (CLL) cells was dexamethasone (DEX) were enhanced by concomitant inhibition of Bruton’s tyrosine kinase and janus kinases (JAKs) motivated a phase II trial to determine if clinical ...
David E. Spaner, Yuxuan Luo, Guizhei Wang, Jennifer Gallagher, Hubert Tsui, Yonghong Shi   +5 more
doaj   +1 more source

JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia [PDF]

, 2017
JAK2 abnormalities may serve as target for precision medicines in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In the current study we performed a screening for JAK2 mutations and translocations, analyzed the clinical outcome and ...
Besselink, N. (Nicolle), Boer, J.M. (Judith), Boer, M.L. (Monique) den, Boeree, A. (Aurélie), de Goffau-Nobel, W. (Willemieke), de Groot-Kruseman, H.A. (Hester A.), Hoogkamer, A.Q. (Alex Q.), Horstmann, M.A. (Martin), Jerchel, I.S. (Isabel S.), Koudijs, M.J. (Marco J.), Pieters, R. (Rob), Steeghs, E.M.P. (Elisabeth M.P.), van de Ven, C. (Cesca), Zwaan, C.M. (Michel)   +13 more
core   +1 more source

Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins

Blood Science, 2023
Ruxolitinib is a cornerstone of management for some subsets of myeloproliferative neoplasms (MPNs); however, a considerable number of patients respond suboptimally.
Huijun Huang, Jinqin Liu, Lin Yang, Yiru Yan, Meng Chen, Bing Li, Zefeng Xu, Tiejun Qin, Shiqiang Qu, Liang Wang, Gang Huang, Yue Chen, Zhijian Xiao   +12 more
doaj   +1 more source

Impaired Antibody Response Following the Second Dose of the BNT162b2 Vaccine in Patients With Myeloproliferative Neoplasms Receiving Ruxolitinib

Frontiers in Medicine, 2022
Data on the effect of ruxolitinib on antibody response to severe acute respiratory coronavirus 2 (SARS-CoV-2) vaccination in patients with myeloproliferative neoplasms (MPN) is lacking.
Daisuke Ikeda, Toshiki Terao, Daisuke Miura, Kentaro Narita, Ami Fukumoto, Ayumi Kuzume, Yuya Kamura, Rikako Tabata, Takafumi Tsushima, Masami Takeuchi, Takaaki Hosoki, Kosei Matsue   +11 more
doaj   +1 more source

TREX1, a predator for treating MSI‐H tumors?

Molecular Oncology, EarlyView.
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya, Joséphine Deneft, Marc Van den Eynde   +2 more
wiley   +1 more source

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling

Nature Communications
Ruxolitinib is a potent JAK1/JAK2 inhibitor, approved for the treatment of primary myelofibrosis (PMF) patients based on the concept of inhibition of oncogenic signaling.
Sivahari Prasad Gorantla, Michael Rassner, Kirstyn Anne Crossley, Tony Andreas Müller, Teresa Poggio, Shifa Khaja Saleem, Helen Kleinfelder, Sudheer Madan Mohan Gambheer, Cornelia Endres, Sabina Schaberg, Dominik Schmidt, Gerin Prince, Irene Gonzalez-Menendez, Detlef Bentrop, Rainer Trittler, Svetlana Rylova, Dietmar Pfeifer, Geoffroy Andrieux, Leticia Quintanilla-Martinez, Anna Lena Illert, Nikolas von Bubnoff, Robert Zeiser, Justus Duyster   +22 more
doaj   +1 more source